Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 794

1.

The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.

Dineen SP, Sullivan LA, Beck AW, Miller AF, Carbon JG, Mamluk R, Wong H, Brekken RA.

BMC Cancer. 2008 Nov 27;8:352. doi: 10.1186/1471-2407-8-352.

3.

Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.

Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R.

Clin Cancer Res. 2000 May;6(5):1936-48.

4.

Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes.

Lang SA, Schachtschneider P, Moser C, Mori A, Hackl C, Gaumann A, Batt D, Schlitt HJ, Geissler EK, Stoeltzing O.

Mol Cancer Ther. 2008 Nov;7(11):3509-18. doi: 10.1158/1535-7163.MCT-08-0373.

5.

Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.

Bocci G, Danesi R, Marangoni G, Fioravanti A, Boggi U, Esposito I, Fasciani A, Boschi E, Campani D, Bevilacqua G, Mosca F, Del Tacca M.

Eur J Pharmacol. 2004 Sep 13;498(1-3):9-18.

PMID:
15363970
6.

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.

Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA.

Mol Cancer Ther. 2009 Jul;8(7):1761-71. doi: 10.1158/1535-7163.MCT-09-0280. Epub 2009 Jun 30.

7.

VEGF-C ShRNA inhibits pancreatic cancer growth and lymphangiogenesis in an orthotopic fluorescent nude mouse model.

Shi Y, Tong M, Wu Y, Yang Z, Hoffman RM, Zhang Y, Tian Y, Qi M, Lin Y, Liu Y, Dai L, Sun Y, Wang Z.

Anticancer Res. 2013 Feb;33(2):409-17.

PMID:
23393331
9.

Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.

Abdelrahim M, Baker CH, Abbruzzese JL, Safe S.

J Natl Cancer Inst. 2006 Jun 21;98(12):855-68.

PMID:
16788159
10.

Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.

Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, Geissler EK, Stoeltzing O, Lang SA.

Mol Cancer Ther. 2011 Nov;10(11):2157-67. doi: 10.1158/1535-7163.MCT-11-0312. Epub 2011 Sep 1.

11.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.

12.

Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.

Solorzano CC, Baker CH, Bruns CJ, Killion JJ, Ellis LM, Wood J, Fidler IJ.

Cancer Biother Radiopharm. 2001 Oct;16(5):359-70.

PMID:
11776753
13.

The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.

Scholz A, Wagner K, Welzel M, Remlinger F, Wiedenmann B, Siemeister G, Rosewicz S, Detjen KM.

Gut. 2009 Feb;58(2):261-70. doi: 10.1136/gut.2007.146415. Epub 2008 Oct 1.

PMID:
18829975
15.
16.

Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer.

Büchler P, Reber HA, Roth MM, Shiroishi M, Friess H, Hines OJ.

Neoplasia. 2007 Feb;9(2):119-27.

17.

Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma.

Solorzano CC, Baker CH, Tsan R, Traxler P, Cohen P, Buchdunger E, Killion JJ, Fidler IJ.

Clin Cancer Res. 2001 Aug;7(8):2563-72.

18.

Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.

Conrad C, Ischenko I, Köhl G, Wiegand U, Guba M, Yezhelyev M, Ryan AJ, Barge A, Geissler EK, Wedge SR, Jauch KW, Bruns CJ.

Anticancer Drugs. 2007 Jun;18(5):569-79.

PMID:
17414626
19.

Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.

Zhu Y, Tibensky I, Schmidt J, Hackert T, Ryschich E, Jäger D, Büchler MW, Märten A.

J Immunother. 2008 Jan;31(1):28-33.

PMID:
18157009
20.

Dual-color imaging of nascent blood vessels vascularizing pancreatic cancer in an orthotopic model demonstrates antiangiogenesis efficacy of gemcitabine.

Amoh Y, Li L, Tsuji K, Moossa AR, Katsuoka K, Hoffman RM, Bouvet M.

J Surg Res. 2006 May 15;132(2):164-9. Epub 2006 Feb 28.

PMID:
16500746

Supplemental Content

Support Center